Literature DB >> 15312251

Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin.

Anna Daroszewska1, Lynne J Hocking, Fiona E A McGuigan, Bente Langdahl, Michael D Stone, Tim Cundy, Geoff C Nicholson, William D Fraser, Stuart H Ralston.   

Abstract

UNLABELLED: To clarify the role of the TNFRSF11B gene encoding osteoprotegerin (OPG), in Paget's disease of bone (PDB) we studied TNFRSF11B polymorphisms in an association study of 690 UK subjects and in a worldwide familial study of 66 kindreds. We found that the G1181 allele of TNFRSF11B, encoding lysine at codon 3 of the OPG protein, predisposes to both sporadic and familial PDB.
INTRODUCTION: Paget's disease of bone (PDB) is a common disorder characterized by focal abnormalities of bone turnover. Genetic factors are important in the pathogenesis of PDB, and studies have shown that inactivating mutations of the TNFRSF11B gene, encoding osteoprotegerin (OPG), cause the rare syndrome of juvenile Paget's disease. In this study, we sought to determine whether polymorphisms of the TNFRSF11B gene contribute to the pathogenesis of classical PDB.
MATERIALS AND METHODS: We screened for polymorphisms of the TNFRSF11B gene by DNA sequencing of the proximal promoter, coding exons, and intron-exon boundaries in 20 PDB patients and 10 controls. Informative single nucleotide polymorphisms (SNPs), including a G1181C SNP, which predicts a lysine-asparagine substitution at codon 3 of the OPG signal peptide and haplotypes, were related to the presence of PDB in 312 cases compared with 378 controls and to transmission of PDB in 140 affected offspring from 66 kindreds with familial PDB. RESULTS AND
CONCLUSIONS: The G1181 allele was significantly over-represented in PDB patients (chi(2) = 5.7, df = 1, p = 0.017, adjusted alpha = 0.024), equivalent to an odds ratio for PDB of 1.55 (95% CI: 1.11-2.16). The distribution of TNFRSF11B haplotypes significantly differed in sporadic PDB cases and controls (chi(2) = 30.2, df = 9, p < 0.001) because of over-representation of haplotypes containing the G1181 allele in cases. The family study showed that the most common haplotype containing the G1181 allele was transmitted more frequently than expected to 140 individuals with familial PDB (chi(2) = 7.35, df = 1, p < 0.01), and the transmission disequilibrium was even more pronounced in a subgroup of 78 familial PDB patients who did not carry mutations of the SQSTM1 gene (chi(2) = 8.44, df = 1, p < 0.005). We conclude that the G1181 allele of TNFRSF11B, encoding lysine at codon 3 of the OPG protein, predisposes to the development of sporadic PDB and familial PDB that is not caused by SQSTM1 mutations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312251     DOI: 10.1359/JBMR.040602

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

1.  The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes.

Authors:  Pui Yan Jenny Chung; Greet Beyens; Steven Boonen; Socrates Papapoulos; Piet Geusens; Marcel Karperien; Filip Vanhoenacker; Leon Verbruggen; Erik Fransen; Jan Van Offel; Stefan Goemaere; Hans-Georg Zmierczak; René Westhovens; Jean-Pierre Devogelaer; Wim Van Hul
Journal:  Hum Genet       Date:  2010-09-14       Impact factor: 4.132

2.  Guidelines for diagnosis and management of Paget's disease of bone in Japan.

Authors:  Shinjiro Takata; Jun Hashimoto; Kiyoshi Nakatsuka; Noriko Yoshimura; Kousei Yoh; Ikko Ohno; Hiroo Yabe; Satoshi Abe; Masao Fukunaga; Masaki Terada; Masaaki Zamma; Stuart H Ralston; Hirotoshi Morii; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

4.  Bone mineral density-affecting genes in Africans.

Authors:  Gordon Gong; Gleb Haynatzki; Vera Haynatzka; Ryan Howell; Sade Kosoko-Lasaki; Yun-Xin Fu; Fei Yu; John C Gallagher; M Roy Wilson
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

5.  Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK.

Authors:  Michael P Whyte; Cristina Tau; William H McAlister; Xiafang Zhang; Deborah V Novack; Virginia Preliasco; Eduardo Santini-Araujo; Steven Mumm
Journal:  Bone       Date:  2014-07-23       Impact factor: 4.398

6.  Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men.

Authors:  Yi-Hsiang Hsu; Tianhua Niu; Henry A Terwedow; Xin Xu; Yan Feng; Zhiping Li; Joseph D Brain; Cliff J Rosen; Nan Laird; Xiping Xu
Journal:  Hum Genet       Date:  2005-10-26       Impact factor: 4.132

Review 7.  Paget's Disease of Bone: Osteoimmunology and Osteoclast Pathology.

Authors:  Emily M Rabjohns; Katlyn Hurst; Arin Ghosh; Maria C Cuellar; Rishi R Rampersad; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-25       Impact factor: 4.806

Review 8.  Pathways in external apical root resorption associated with orthodontia.

Authors:  J K Hartsfield
Journal:  Orthod Craniofac Res       Date:  2009-08       Impact factor: 1.826

9.  Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss.

Authors:  Shyan-Yuan Kao; Judith S Kempfle; Jane B Jensen; Deborah Perez-Fernandez; Andrew C Lysaght; Albert S Edge; Konstantina M Stankovic
Journal:  Neurobiol Dis       Date:  2013-04-20       Impact factor: 5.996

10.  Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures.

Authors:  S Jurado; X Nogués; L Agueda; N Garcia-Giralt; R Urreizti; G Yoskovitz; L Pérez-Edo; G Saló; R Carreras; L Mellibovsky; S Balcells; D Grinberg; A Díez-Pérez
Journal:  Osteoporos Int       Date:  2009-05-13       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.